BFM
ANRO icon

Boothbay Fund Management’s Alto Neuroscience ANRO Stock Holding History

Boothbay Fund Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-131,600
Closed -$1.51M – 1969
2024
Q3 		$1.51M Buy
+131,600
New +$1.61M 0.03% 617

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Boothbay Fund Management's ANRO Position: Q2 2026 in Review

Boothbay Fund Management reduced its Alto Neuroscience (ANRO) stake by 24% in Q2 2026, selling an estimated $765K and leaving 106,234 shares worth $2.8M. The position accounts for 0.04% of the portfolio, ranked #569.

Boothbay Fund Management first reported a position in ANRO in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.13M in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Boothbay Fund Management held 106,234 shares of Alto Neuroscience worth $2.8M as of Q2 2026.
  • Boothbay Fund Management sold 33,070 Alto Neuroscience shares in Q2 2026, an estimated $765K.
  • Alto Neuroscience made up 0.04% of Boothbay Fund Management's portfolio in Q2 2026, its #569 holding.
  • Boothbay Fund Management first reported a position in Alto Neuroscience in Q4 2024 and has held it in 7 quarters since.
  • Boothbay Fund Management's Alto Neuroscience position peaked at $3.13M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.